Intravenous tissue plasminogen activator thrombolysis in patients with diabetes mellitus and previous stroke.
Gonzalez-Hernandez
Ayoze N
AN
Fabre-Pi
Oscar
O
Lopez-Fernandez
Juan C
JC
Diaz-Nicolas
Santiago
S
D015984:Causality; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D000075202:Contraindications; D048909:Diabetes Complications / Q000503:physiopathology*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D020767:Intracranial Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008487:Medical History Taking; D018579:Patient Selection; D018570:Risk Assessment; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator